|
Today's Headlines
FDA is requiring color changes to the printing on fentanyl (Duragesic) pain patches so that it is clearly visible, to help avoid risk of accidental exposure. Accidental exposure to these patches that contain a narcotic opioid can cause serious harm and death in children, pets, and others.
» Full article
|
|
FDA has approved ustekinumab (Stelara, Janssen Biotech) alone or in combination with methotrexate for active psoriatic arthritis in adult patients aged 18 years and older. » Full article
|
|
The Office of Disease Prevention and Health Promotion under the Department of Health and Human Services is calling for public review and comments on its draft plan to reduce adverse drug events that are preventable. The deadline is Friday, Oct. 4 to email feedback to ADE@hhs.gov. » Full article
|
|
A new report by the US Centers for Disease Control and Prevention said millions of Americans are at risk from drug-resistant superbugs that cause gonorrhea, C difficile, and carbapenem-resistant Enterobacteriaceae. » Full article
|
Continuing Education
This month, Drug Topics offers the first part of a two-part CPE series, "MTM considerations in osteoporosis care." Earn up to 2 credits by completing this application-based activity.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in.
Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide
or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at
www.MyCPEmonitor.net. This profile will enable you to have one login
for all the NABP programs and services you will need throughout your career.
|
|
|
EDITOR'S PICK
New regulations in the Patient Protection and Affordable Care Act have led to the birth of essential health benefits. CMS' new division, the Center for Consumer Information and Insurance Oversight (CCIIO), is responsible for the oversight of the insurance offerings on the new health insurance exchanges, which have 10 required essential health benefit categories. One of these essential categories is prescription drugs. Prospective qualified health plans, pharmacy benefit managers, and consultant agencies have struggled through the legislation and guidance from CCIIO in an attempt to build benefits that meet the requirements. With elements of typical commercial offerings as well as those of Medicare Part D, there are many nuances that one must consider when building an exchange formulary and creating the surrounding benefit.
» Full article |
|
|
Like
Tweet
